Biomanufacturing for clinically advanced cell therapies

Ayesha Aijaz, Matthew Li, David Smith, Danika Khong, Courtney Leblon, Owen S. Fenton, Ronke Olabisi, Steven Libutti, Jay Tischfield, Marcela V. Maus, Robert Deans, Rita N. Barcia, Daniel G. Anderson, Jerome Ritz, Robert Preti, Biju Parekkadan

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

The achievements of cell-based therapeutics have galvanized efforts to bring cell therapies to the market. To address the demands of the clinical and eventual commercial-scale production of cells, and with the increasing generation of large clinical datasets from chimeric antigen receptor T-cell immunotherapy, from transplants of engineered haematopoietic stem cells and from other promising cell therapies, an emphasis on biomanufacturing requirements becomes necessary. Robust infrastructure should address current limitations in cell harvesting, expansion, manipulation, purification, preservation and formulation, ultimately leading to successful therapy administration to patients at an acceptable cost. In this Review, we highlight case examples of cutting-edge bioprocessing technologies that improve biomanufacturing efficiency for cell therapies approaching clinical use.

Original languageEnglish (US)
Pages (from-to)362-376
Number of pages15
JournalNature biomedical engineering
Volume2
Issue number6
DOIs
StatePublished - Jun 1 2018

Fingerprint

Transplants
T-cells
Antigens
Cell- and Tissue-Based Therapy
T-Cell Antigen Receptor
Stem cells
Purification
Costs
Antigen Receptors
Hematopoietic Stem Cells
Immunotherapy
Technology
Efficiency
Costs and Cost Analysis
Therapeutics

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Computer Science Applications

Cite this

Aijaz, Ayesha ; Li, Matthew ; Smith, David ; Khong, Danika ; Leblon, Courtney ; Fenton, Owen S. ; Olabisi, Ronke ; Libutti, Steven ; Tischfield, Jay ; Maus, Marcela V. ; Deans, Robert ; Barcia, Rita N. ; Anderson, Daniel G. ; Ritz, Jerome ; Preti, Robert ; Parekkadan, Biju. / Biomanufacturing for clinically advanced cell therapies. In: Nature biomedical engineering. 2018 ; Vol. 2, No. 6. pp. 362-376.
@article{edc7f29047a047dfb46897ab92c9f636,
title = "Biomanufacturing for clinically advanced cell therapies",
abstract = "The achievements of cell-based therapeutics have galvanized efforts to bring cell therapies to the market. To address the demands of the clinical and eventual commercial-scale production of cells, and with the increasing generation of large clinical datasets from chimeric antigen receptor T-cell immunotherapy, from transplants of engineered haematopoietic stem cells and from other promising cell therapies, an emphasis on biomanufacturing requirements becomes necessary. Robust infrastructure should address current limitations in cell harvesting, expansion, manipulation, purification, preservation and formulation, ultimately leading to successful therapy administration to patients at an acceptable cost. In this Review, we highlight case examples of cutting-edge bioprocessing technologies that improve biomanufacturing efficiency for cell therapies approaching clinical use.",
author = "Ayesha Aijaz and Matthew Li and David Smith and Danika Khong and Courtney Leblon and Fenton, {Owen S.} and Ronke Olabisi and Steven Libutti and Jay Tischfield and Maus, {Marcela V.} and Robert Deans and Barcia, {Rita N.} and Anderson, {Daniel G.} and Jerome Ritz and Robert Preti and Biju Parekkadan",
year = "2018",
month = "6",
day = "1",
doi = "10.1038/s41551-018-0246-6",
language = "English (US)",
volume = "2",
pages = "362--376",
journal = "Nature Biomedical Engineering",
issn = "2157-846X",
publisher = "Nature Publishing Group",
number = "6",

}

Aijaz, A, Li, M, Smith, D, Khong, D, Leblon, C, Fenton, OS, Olabisi, R, Libutti, S, Tischfield, J, Maus, MV, Deans, R, Barcia, RN, Anderson, DG, Ritz, J, Preti, R & Parekkadan, B 2018, 'Biomanufacturing for clinically advanced cell therapies', Nature biomedical engineering, vol. 2, no. 6, pp. 362-376. https://doi.org/10.1038/s41551-018-0246-6

Biomanufacturing for clinically advanced cell therapies. / Aijaz, Ayesha; Li, Matthew; Smith, David; Khong, Danika; Leblon, Courtney; Fenton, Owen S.; Olabisi, Ronke; Libutti, Steven; Tischfield, Jay; Maus, Marcela V.; Deans, Robert; Barcia, Rita N.; Anderson, Daniel G.; Ritz, Jerome; Preti, Robert; Parekkadan, Biju.

In: Nature biomedical engineering, Vol. 2, No. 6, 01.06.2018, p. 362-376.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Biomanufacturing for clinically advanced cell therapies

AU - Aijaz, Ayesha

AU - Li, Matthew

AU - Smith, David

AU - Khong, Danika

AU - Leblon, Courtney

AU - Fenton, Owen S.

AU - Olabisi, Ronke

AU - Libutti, Steven

AU - Tischfield, Jay

AU - Maus, Marcela V.

AU - Deans, Robert

AU - Barcia, Rita N.

AU - Anderson, Daniel G.

AU - Ritz, Jerome

AU - Preti, Robert

AU - Parekkadan, Biju

PY - 2018/6/1

Y1 - 2018/6/1

N2 - The achievements of cell-based therapeutics have galvanized efforts to bring cell therapies to the market. To address the demands of the clinical and eventual commercial-scale production of cells, and with the increasing generation of large clinical datasets from chimeric antigen receptor T-cell immunotherapy, from transplants of engineered haematopoietic stem cells and from other promising cell therapies, an emphasis on biomanufacturing requirements becomes necessary. Robust infrastructure should address current limitations in cell harvesting, expansion, manipulation, purification, preservation and formulation, ultimately leading to successful therapy administration to patients at an acceptable cost. In this Review, we highlight case examples of cutting-edge bioprocessing technologies that improve biomanufacturing efficiency for cell therapies approaching clinical use.

AB - The achievements of cell-based therapeutics have galvanized efforts to bring cell therapies to the market. To address the demands of the clinical and eventual commercial-scale production of cells, and with the increasing generation of large clinical datasets from chimeric antigen receptor T-cell immunotherapy, from transplants of engineered haematopoietic stem cells and from other promising cell therapies, an emphasis on biomanufacturing requirements becomes necessary. Robust infrastructure should address current limitations in cell harvesting, expansion, manipulation, purification, preservation and formulation, ultimately leading to successful therapy administration to patients at an acceptable cost. In this Review, we highlight case examples of cutting-edge bioprocessing technologies that improve biomanufacturing efficiency for cell therapies approaching clinical use.

UR - http://www.scopus.com/inward/record.url?scp=85048377439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048377439&partnerID=8YFLogxK

U2 - 10.1038/s41551-018-0246-6

DO - 10.1038/s41551-018-0246-6

M3 - Review article

VL - 2

SP - 362

EP - 376

JO - Nature Biomedical Engineering

JF - Nature Biomedical Engineering

SN - 2157-846X

IS - 6

ER -

Aijaz A, Li M, Smith D, Khong D, Leblon C, Fenton OS et al. Biomanufacturing for clinically advanced cell therapies. Nature biomedical engineering. 2018 Jun 1;2(6):362-376. https://doi.org/10.1038/s41551-018-0246-6